Real world evaluation of lipoprotein (a) testing and impact on LDL-C management in atherosclerotic cardiovascular disease patients: findings from the CVMOBIUS2 registry
Oct 2026· European Heart Journal· Vol 47· 0 citations
TL;DR
Electronic health record data from 17 US health systems between 1/1/2021-12/31/2024 were analyzed to determine the prevalence of Lp(a) testing among adults with ASCVD and changes in LDL-C management in those who are identified to have elevated Lp(a) levels.
Abstract
Current guidelines recommend testing Lp(a) to identify adults with elevated levels who may need further intensification of treatments to manage other cardiovascular risk factors, such as low density lipoprotein cholesterol (LDL-C) levels. Despite the rising knowledge of Lp(a), it is unclear whether this has translated to increased Lp(a) testing and how testing impacts contemporary LDL-C management in patients with ASCVD in clinical practice.
To understand trends in testing of Lp(a) in patients with ASCVD in the United States and changes in LDL-C management in those who are identified to have elevated Lp(a) levels.
Electronic health record (EHR) data from 17 US health systems between 1/1/2021-12/31/2024 were analyzed to determine the prevalence of Lp(a) testing among adults with ASCVD. Lp(a) levels in mg/dL were approximated to nmol/L using the formula 2.18*Lp(a) (in mg/dL) – 3.821. The percent of ASCVD patients who underwent Lp(a) testing each year was evaluated overall and stratified by age, sex, race, and ethnicity. Of those tested, the proportions with elevated Lp(a) levels were also assessed. Changes in LDL-C lowering therapy after Lp(a) testing were evaluated overall and stratified by Lp(a) levels.
A total of 2,378,652 patients with ASCVD were included in the study, of which only 36,410 (1.5%) ever had an Lp(a) test. Most (73.0%) tests were performed as molar assays (nmol/L) while 28.0% were mass-based assays (mg/dL). A small incremental increase in testing was observed from 2021 through 2024 (0.2% in 2021, 0.3% in 2022, 0.5% in 2023, and 0.7% in 2024). Testing was more common in younger individuals: 3.1% of those age 18-40 and 3.0% of those 41-60 years underwent testing, while only 1.4% of those age 61-80 and 0.4% of those >80 years ever had a test. No major differences in testing patterns were seen by sex, race, or ethnicity. Of those tested, 29.9% had an Lp(a) > 125 nmol/L, and 17% had Lp(a) ≥ 200 nmol/L. Non-Hispanic Black patients had the highest proportion of elevated Lp(a) (51.8% with ≥ 125 nmol/L and 31.1% ≥ 200 nmol/L.). LDL-C lowering therapy was more frequently intensified in those with higher Lp(a) levels (Table), with LDL-C lowering therapeutic intensification occurring in 50.1% of those with Lp(a) ≥200 nmol/L compared to 36.8% in those with <125 nmol/L (p <0.001).
Despite rising evidence and guideline support to modify risk associated with elevated Lp(a), testing rates remain low. When tested, those with elevated Lp(a) levels were more likely to undergo intensification of LDL-C lowering therapy.LDL-C lowering therapy changes
Background:
Elevated lipoprotein(a) [Lp(a)] is an independent, genetically determined causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and can refine risk assessment and, in the absence of targeted therapies, inform lipid lowering therapy (LLT) decisions. Although clinical guidelines recommend m...
Ding-Wei Dai, Xing-Di Hu, A. Khakwani et al.· Circulation· 0 citations
Elevated lipoprotein(a) [Lp(a)] is a recognized cardiovascular risk factor, but its association with subsequent lipid-lowering treatment (LLT) patterns is unclear. We assessed whether higher Lp(a) levels were associated with recorded post-test changes in lipid-lowering therapy (LLT).
This retrospective obser...
Beata Bobrowska, Z. Siudak, Justyna Domienik-Karłowicz et al.· Archives of Medical Science· 0 citations
Background Though elevated lipoprotein (a) (Lp[a]) is associated with ASCVD and testing is recommended for all adults, how to use Lp(a) for decision-making in low-risk patients remains uncertain. Methods We studied low-risk adults in a large healthcare system, excluding those on statins or with statin indications in th...
K. F. Faridi, Qi-Fan Wu, E. Spatz et al.· American Heart Journal Plus:...· 0 citations
Lp(a) is a causal risk factor for atherosclerotic cardiovascular disease(ASCVD) and calcific valvular aortic stenosis. Traditionally, major guidelines recommended targeted Lp(a) measurement for patients with familial hypercholesterolemia, premature ASCVD, or individuals at moderate ASCVD risk to improve risk clas...
Jun G. Tan, Moh Sim Wong, P. Heng et al.· Clinical Chemistry· 0 citations
Therapeutics that dramatically lower lipoprotein(a) (Lp(a)) currently in phase 3 testing have enrolled participants with concentrations above certain thresholds, e.g., ≥70 mg/dL or ≥150 nmol/L. Although repeated testing of Lp(a) is generally viewed as unnecessary due to the fact that concentrations are primarily...
M. Szarek, D. L. Bhatt, M. Miller et al.· European Heart Journal· 0 citations
Background:
Elevated lipoprotein(a) [Lp(a)] is a heritable, independent risk factor for atherosclerotic cardiovascular disease, and it is not meaningfully reduced by statins or ezetimibe. Whether elevated Lp(a) translates into measurable residual cardiovascular and limb ischemic risk in patients who have achieved an...
Maryam Mojarrad Sani, A. Nouri, Ashkan Abdollahi et al.· Circulation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.